Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMM0N1F)

Drug Name

AZD-0865 Drug Info

Synonyms

AR-H044277

Indication

Disease Entry	ICD 11	Status	REF
Gastrointestinal disease	DE2Z	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Gastric H(+)/K(+) ATPase (Proton pump)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[3]
Pantoprazole	DMSVOCZ	Gastrinoma	2C10.1	Approved	[3]
Dexlansoprazole	DM1DBV5	Erosive esophagitis	DA25.0	Approved	[3]
Esomeprazole	DM7BN0X	Cystic fibrosis	CA25	Approved	[3]
Vonoprazan	DMO6315	Helicobacter infection	DA42-DA63	Approved	[4]
RQ-00000004	DM9T8OF	Gastroesophageal reflux disease	DA22.Z	Phase 3	[5]
YH-4808	DMCHFB0	Duodenal ulcer	DA63	Phase 2	[6]
S-tenatoprazole	DMJ1DIB	Peptic ulcer	DA61	Phase 2	[7]
LEMINOPRAZOLE	DMBKNJT	Ulcerative colitis	DD71	Discontinued in Preregistration	[8]
SKF-96067	DMXW1Y3	Peptic ulcer	DA61	Discontinued in Phase 3	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Gastric H(+)/K(+) ATPase (Proton pump)	TTLOKXP	ATP4A_HUMAN; ATP4B_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00206284) A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis.. U.S. National Institutes of Health.
2	Mechanism of action of AZD0865, a K+-competitive inhibitor of gastric H+,K+-ATPase. Biochem Pharmacol. 2007 Jan 15;73(2):198-205.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2008
5	N-(2-hydroxyethyl)-N,2-dimethyl-8-{[(4R)-5-methyl-3,4-dihydro-2H-chromen-4-yl]amino}imidazo[1,2-a]pyridine-6-carboxamide (PF-03716556), a novel, potent, and selective acid pump antagonist for the treatment of gastroesophageal reflux disease. J Pharmacol Exp Ther. 2009 Feb;328(2):671-9.
6	Poor effectiveness of proton pump inhibitors in non-erosive reflux disease: the truth in the end! Neurogastroenterol Motil.2012 Aug;24(8):697-704.
7	Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in heal... Aliment Pharmacol Ther. 2004 Mar 15;19(6):655-62.
8	Vasoinhibitory effect of leminoprazole, a H+,K(+)-ATPase inhibitor, on rat aortic rings. Gen Pharmacol. 1996 Jan;27(1):117-21.
9	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.